SEARCH

SEARCH BY CITATION

References

  • 1
    Ohno Y, Nakamura T, Oshima A et al. The future estimates of cancer prevalence rate in Japan. In: OshimaA, KuroishiT, TajimaK (eds). Gan Tohkei Hakusho-Morbidity/Death/Prognosis-2004. Shinohara Publisher, Tokyo, 2004; 201217.
  • 2
    Cancer Statistics in Japan ′03: Age-adjusted Death Rates of Malignant Neoplasms by Site, Sex and Calendar Year (1950–2001). [Cited 27 July 2004.] Available from URL: http://www.ncc.go.jp/jp/statistics/2003/data05.pdf
  • 3
    Yatani R, Chigusa I, Akazaki K et al. Geographic pathology of latent prostatic carcinoma. Int. J. Cancer 1982; 29: 61116.
  • 4
    Etzioni R, Cha R, Feuer EJ et al. Asymptomatic incidence and duration of prostate cancer. Am. J Epidemiol. 1998; 148: 77585.
  • 5
    Hiraishi T et al. Latent Prostatic Carcinoma. Clinical Practice Manual for Prostate Cancer, The Japanese Foundation for Prostate Research, Kanehara & Co., LTD., Tokyo, 1995; 1324.
  • 6
    Watanabe H. Studies on the Natural History of Prostate Cancer. Clinical Practice Manual for Prostate Cancer, The Japanese Foundation for Prostate Research, Kanehara & Co., LTD., Tokyo, 1995; 112.
  • 7
    Fukuta F, Masumori N, Tanaka Y et al. The detection rate of prostate cancer in outpatients presenting lower urinary tract symptoms. Jpn. J. Clin. Urol. 2005; 59: 1338.
  • 8
    Lepor H, Owens RS, Rogenes V et al. Detection of prostate cancer in males with prostatism. Prostate 1994; 25: 13240.
  • 9
    Steinberg GD, Carter BS, Beaty TH et al. Family history and the risk of prostate cancer. Prostate 1990; 17: 33747.
  • 10
    Giovannucci E, Rimm EB, Colditz GA et al. A prospective study of dietary fat and risk of prostate cancer. J. Natl. Cancer Inst. 1993; 85: 15719.
  • 11
    Nakata S, Imai K, Yamanaka H, Yashima H. Correlation Analysis between Mortality for Prostate Cancer and Dietary Pattern in Japan and the World. Jpn. J. Cancer Clin. 1994; 40: 8316.
  • 12
    Hebert JR, Hurley TG, Olendzki BC et al. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J. Natl. Cancer Inst. 1998; 90: 163747.
  • 13
    Eichholzer M, Stahelin HB, Ludin E et al. Smoking, plasma vitamins C, E, retinol, and carotene, and fatal prostate cancer: seventeen-year follow-up of the prospective Basel study. Prostate 1999: 38: 18998.
  • 14
    Clark LC, Dalkin B, Krongrad A et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br. J. Urol. 1998; 81: 7304.
  • 15
    Hartman TJ, Albanes D, Pietinen P et al. The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol. Biomarkers Prev. 1998; 7: 33540.
  • 16
    Smith RA, Cokkinides V, Eyre HJ et al. American Cancer Society guidelines for the early detection of cancer, 2004. CA Cancer J. Clin. 2004; 54: 4152.
  • 17
    American Urological Association (AUA). Prostate-specific antigen (PSA) best practice policy. Oncology (Williston Park) 2000; 14: 26772, 277–28, 280 passim.
  • 18
    Recommendations and Rationale. Screening for Prostate Cancer: U.S. Preventive Services Task Force (USPSTF). [Cited 12 November 2004.] Available from URL: http://www.ahcpr.gov/clinic/3rduspstf/prostatescr/prostaterr.htm
  • 19
    Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2002; 137: 91729.
  • 20
    Roberts RO, Bergstralh EJ, Katusic SK et al. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J. Urol. 1999; 161: 52933.
  • 21
    Meyer F, Moore L, Bairati I et al. Downward trend in prostate cancer mortality in Quebec and Canada. J. Urol. 1999; 161: 118991.
  • 22
    Bartsch G, Horninger W, Klocker H et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001; 58: 41724.
  • 23
    Prorok PC, Andriole GL, Bresalier RS et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. Control. Clin. Trials 2000; 21 (6 Suppl): 273S309S.
  • 24
    Schröder FH, Denis LJ, Roobol M et al. The story of the European randomized study of screening for prostate cancer. BJU Int. 2003; 92 (Suppl 2): 113.
  • 25
    The Prostate Cancer Screening Council, The Japanese Foundation for Prostate Research. The survey of prostate cancer screening tests in Ningen Dock in Japan (1989–1999). The survey of prostate cancer mass screening in Japan (1986–1999). Jpn. J. Urol. Surg. 2003; 16: 102338.
  • 26
    Kubota Y, Ito K, Imai K et al. Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities. Prostate 2002; 50: 2629.
  • 27
    Ito K, Yamamoto T, Suzuki K et al. The risk of rapid prostate specific antigen increase in men with baseline prostate specific antigen 20 ng/ml or less. J. Urol. 2004; 171: 65660.
  • 28
    Ito K, Yamamoto T, Ohi M et al. Possibility of re-screening intervals of more than one year in men with PSA levels of 40 ng/ml or less. Prostate 2003; 57: 813.
  • 29
    Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int. J. Urol. 2005; 12: 4661.
  • 30
    Chodak GW. Early detection and screening for prostatic cancer. Urology 1989; 34: 10.
  • 31
    Pedersen KV, Carlsson P, Varenhorst E et al. Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. BMJ 1990; 300: 1041.
  • 32
    Catalona WJ, Richie JP, Ahmann FR et al. Comparison of digital rectal examination and serum prostate specific antigen (PSA) in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J. Urol. 1994; 151: 128390.
  • 33
    Haas GP, Monyie JE, Pontes JE. The state of prostate cancer screening in the United States. Eur. Urol. 1993; 23: 33747.
  • 34
    Gretzer MB, Partin AW. PSA markers in prostate cancer detection. Urol. Clin. North Am. 2003; 30: 67786.
  • 35
    Okihara K, Cheli CD, Partin AW et al. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J. Urol. 2002; 167: 201723.
  • 36
    Elgamal AA, van Poppel HP, van de Voorde WM et al. Impalpable, invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens–a different view. J. Urol. 1997; 157: 24450.
  • 37
    Gustavsson O, Norming U, Almgard LE et al. Diagnostic methods in the detection of prostate cancer: a study of a randomly selected population of 2400 men. J. Urol. 1992; 148: 182731.
  • 38
    Mettlin C, Murphy GP, Babaian RJ et al. The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer 1996; 77: 1509.
  • 39
    Punglia RS, D'Amico AV, Catalona WJ et al. Effect of verification bias on screening for prostate cancer by measurement of prostate–specific antigen. N. Engl. J. Med. 2003; 349: 33542.
  • 40
    Hodge KK, McNeal JE, Terris MK et al. Random systemic versus directed ultrasound guided transrectal core biopsies of the prostate. J. Urol. 1989; 142: 714.
  • 41
    Emiliozzi P, Corsetti A, Tassi B et al. Best approach for prostate cancer detection: a prospective study on transperineal versus transrectal six-core prostate biopsy. Urology 2003; 61: 9616.
  • 42
    Emiliozzi P, Longhi S, Scarpone P et al. The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen. J. Urol. 2001; 166: 84550.
  • 43
    Raaijmakers R, Kirkels WJ, Roobol MJ et al. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. The Neth. Urol. 2002; 60: 82630.
  • 44
    Babaian RJ, Toi A, Kamoi K et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J. Urol. 2000; 163: 1527.
  • 45
    Presti JC Jr, Chang JJ, Bhargava V et al. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J. Urol. 2000; 163: 1636; discussion 166–7.
  • 46
    Keetch DW, Catalona WJ, Smith DS. Serial prostate biopsies in men with persistently elevated serum prostate specific antigen levels. J. Urol. 1994; 151: 15714.
  • 47
    Roerhborn CG, Pickers GJ, Sanders JS. Diagnostic yield of repeated ultrasound guided biopsies stratified by specific histopathologic diagnosis and prostate specific antigen levels. Urology 1996; 47: 34752.
  • 48
    Zlotta AR, Raviv G, Schulman CC. Clinical prognostic criteria for later diagnosis of prostate carcinoma in patients with initial isolated prostatic intraepithelial neoplasia. Eur. Urol. 1996; 30: 24955.
  • 49
    Haggman MJ, Macoska JA, Wojno KJ et al. The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. J. Urol. 1997; 158: 1222.
  • 50
    Spigelman SS, McNeal JE, Freiha FS et al. Rectal examination in volume determination of carcinoma of the prostate: clinical and anatomical correlations. J. Urol. 1986; 136: 122830.
  • 51
    Partin AW, Mangold LA, Lamm DM et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58: 8438.
  • 52
    Rorvik J, Halvorsen OJ, Servoll E et al. Transrectal ultrasonography to assess local extent of prostatic cancer before radical prostatectomy. Br. J. Urol. 1994; 73: 659.
  • 53
    Lee N, Newhouse JH, Olsson CA et al. Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients. Urology 1999; 54: 4904.
  • 54
    Jager GJ, Severens JL, Thornbury JR et al. Prostate cancer staging: should MR imaging be used? A decision analytic approach. Radiology 2000; 215: 44551.
  • 55
    Heenan SD. Magnetic resonance imaging in prostate cancer. Prostate Cancer Prostatic Dis. 2004; 7: 2828.
  • 56
    Partin AW, Yoo J, Carter HB et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol. 1993; 150: 11014.
  • 57
    Whitmore WF Jr. Natural history and staging of prostate cancer. Urol. Clin. North Am. 1984; 11: 20920.
  • 58
    Gerber G, Chodak GW. Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer. Urology 1991; 37: 41822.
  • 59
    Soloway MS, Hardeman SW, Hickey D et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195202.
  • 60
    Rana A, Karamanis K, Lucas MG et al. Identification of metastatic disease by T category, Gleason score and serum PSA level in patients with carcinoma of the prostate. Br. J. Urol. 1992; 69: 27781.
  • 61
    Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. 1991; 145: 90723.
  • 62
    Oesterling JE. Using PSA to eliminate the staging radionuclide bone scan. Significant economic implications. Urol. Clin. North Am. 1993; 20: 70511.
  • 63
    Nakayama T. Guide to Developing and Using Evidence-Based Practice Guidelines. Kanehara & Co., LTD., Tokyo, 2004.
  • 64
    D'Amico AV, Moul JW, Carroll PR et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J. Natl. Cancer Inst. 2003; 95: 137683.
  • 65
    Iselin CE, Robertson JE, Paulson DF. Radical perineal prostatectomy: oncological outcome during a 20-year period. J. Urol. 1999; 161: 1638.
  • 66
    D'Amico AV. Predicting prostate-specific antigen recurrence established: now, who will survive? J. Clin. Oncol. 2002; 20: 318890.
  • 67
    Schild SE, Wong WW, Novicki DE et al. Detection of residual prostate cancer after radical prostatectomy with the Abbott IMx PSA assay. Urology 1996; 47: 87881.
  • 68
    Oefelein MG, Smith N, Carter M et al. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J. Urol. 1995; 154: 212831.
  • 69
    Pound CR, Partin AW, Eisenberger MA et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 15917.
  • 70
    Scher HI. Management of prostate cancer after prostatectomy: treating the patient, not the PSA. JAMA 1999; 281: 16425.
  • 71
    Lu–Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997; 349 (9056): 90610.
  • 72
    Graversen PH, Nielsen KT, Gasser TC et al. Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen-year follow-up. Urology 1990; 36: 4938.
  • 73
    Barry MJ, Albertsen PC, Bagshaw MA et al. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer 2001; 91: 230214.
  • 74
    Holmberg L, Bill-Axelson A, Helgesen F et al. Scandinavian Prostatic Cancer Group Study Number 4. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N. Engl. J. Med. 2002; 347: 7819.
  • 75
    Elgamal AA, Van Poppel HP, Van de Voorde WM et al. Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens–a different view. J. Urol. 1997; 157: 24450.
  • 76
    Oesterling JE, Suman VJ, Zincke H et al. PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors. Urol. Clin. North Am. 1993; 20: 68793.
  • 77
    Epstein JI, Walsh PC, Brendler CB. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). J. Urol. 1994; 152: 17219.
  • 78
    Gibbons RP. Total prostatectomy for clinically localized prostate cancer: long-term surgical results and current morbidity. NCI Monogr. 1988; 7: 1236.
  • 79
    Pound CR, Partin AW, Epstein JI et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol. Clin. North Am. 1997; 24: 395406.
  • 80
    Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J. Urol. 1994; 152: 183742.
  • 81
    Trapasso JG, deKernion JB, Smith RB et al. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J. Urol. 1994; 152: 18215.
  • 82
    Zincke H, Oesterling JE, Blute ML et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J. Urol. 1994; 152: 18507.
  • 83
    Han M, Partin AW, Pound CR et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol. Clin. North Am. 2001; 28: 55565.
  • 84
    Hull GW, Rabbani F, Abbas F et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J. Urol. 2002; 167: 52834.
  • 85
    Lau WK, Bergstralh EJ, Blute ML et al. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J. Urol. 2002; 167: 11722.
  • 86
    van den Ouden D, Hop WC, Schroder FH. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J. Urol. 1998; 160: 13927.
  • 87
    Alibhai SM, Naglie G, Nam R et al. Do older men benefit from curative therapy of localized prostate cancer? J. Clin. Oncol. 2003; 21: 331827.
  • 88
    Coen JJ, Zietman AL, Shipley WU. Prostatectomy or watchful waiting in prostate cancer. N. Engl. J. Med. 2003; 348: 1701;author reply 170–1.
  • 89
    Grimm MO, Kamphausen S, Hugenschmidt H et al. Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation. Eur. Urol. 2002; 41: 62834.
  • 90
    Lu-Yao GL, McLerran D, Wasson J et al. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA 1993; 269: 26336.
  • 91
    Eastham JA, Kattan MW, Riedel E et al. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J. Urol. 2003; 170: 22925.
  • 92
    Van Poppel H, Collette L, Kirkali Z et al. EORTC GU Group. Quality control of radical prostatectomy: a feasibility study. Eur. J. Cancer 2001; 37: 8849.
  • 93
    Soloway MS, Pareek K, Sharifi R et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J. Urol. 2002; 167: 11216.
  • 94
    Aus G, Abrahamsson PA, Ahlgren G et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int. 2002; 90: 5616.
  • 95
    Klotz LH, Goldenberg SL, Jewett MA et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J. Urol. 2003; 170: 7914.
  • 96
    Salomon L, Anastasiadis AG, Levrel O et al. Location of positive surgical margins after retropubic, perineal, and laparoscopic radical prostatectomy for organ-confined prostate cancer. Urology 2003; 61: 38690.
  • 97
    Artibani W, Grosso G, Novara G et al. Is laparoscopic radical prostatectomy better than traditional retropubic radical prostatectomy? An analysis of peri-operative morbidity in two contemporary series in Italy. Eur. Urol. 2003; 44: 4016.
  • 98
    Lance RS, Freidrichs PA, Kane C et al. A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group. BJU Int. 2001; 87: 615.
  • 99
    Lodding P, Bergdahl C, Nyberg M et al. Inguinal hernia after radical retropubic prostatectomy for prostate cancer: a study of incidence and risk factors in comparison to no operation and lymphadenectomy. J. Urol. 2001; 166: 9647.
  • 100
    Lu–Yao GL, Albertsen P, Warren J et al. Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy – a population-based study. Urology 1999; 54: 3017.
  • 101
    Bishoff JT, Motley G, Optenberg SA et al. Incidence of fecal and urinary incontinence following radical perineal and retropubic prostatectomy in a national population. J. Urol. 1998; 160: 4548.
  • 102
    Abbou CC, Salomon L, Hoznek A et al. Laparoscopic radical prostatectomy: preliminary results. Urology 2000; 55: 6304.
  • 103
    Guillonneau B, el-Fettouh H, Baumert H et al. Laparoscopic radical prostatectomy: oncological evaluation after 1,000 cases a Montsouris Institute. J. Urol. 2003; 169: 12616.
  • 104
    Rassweiler J, Sentker L, Seemann O et al. Laparoscopic radical prostatectomy with the Heilbronn technique: an analysis of the first 180 cases. J. Urol. 2001; 166: 21018.
  • 105
    Arai Y, Egawa S, Terachi T et al. Morbidity of laparoscopic radical prostatectomy: summary of early multi-institutional experience in Japan. Int. J. Urol. 2003; 10: 4304.
  • 106
    Marcovich R, Wojno KJ, Wei JT et al. Bladder neck-sparing modification of radical prostatectomy adversely affects surgical margins in pathologic T3a prostate cancer. Urology 2000; 55: 9048.
  • 107
    Stanford JL, Feng Z, Hamilton AS et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000; 283: 35460.
  • 108
    Sokoloff MH, Brendler CB. Indications and contraindications for nerve-sparing radical prostatectomy. Urol. Clin. North Am. 2001; 28: 53543.
  • 109
    Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2002; 54: 10638.
  • 110
    Clark T, Parekh DJ, Cookson MS et al. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J. Urol. 2003; 169: 1457.
  • 111
    Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J. Urol. 2002; 167: 16816.
  • 112
    Freedland SJ, Sutter ME, Dorey F et al. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003; 61: 3659.
  • 113
    Leibman BD, Dillioglugil O, Wheeler TM et al. Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. Cancer 1995; 76: 25304.
  • 114
    Lattouf JB, Saad F. Digital rectal exam following prostatectomy: is it still necessary with the use of PSA? Eur. Urol. 2003; 43: 3336.
  • 115
    Niwakawa M, Tobisu K, Fujimoto H et al. Medically and economically appropriate follow-up schedule for prostate cancer patients after radical prostatectomy. Int. J. Urol. 2002; 9: 13440.
  • 116
    Messing EM, Manola J, Sarosdy M et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl. J. Med. 1999; 341: 17818.
  • 117
    Pisansky TM, Kozelsky TF, Myers RP et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J. Urol. 2000; 163: 84550.
  • 118
    Duchesne GM, Dowling C, Frydenberg M et al. Outcome, morbidity, and prognostic factors in post-prostatectomy radiotherapy: an Australian multicenter study. Urology 2003; 61: 17983.
  • 119
    Song DY, Thompson TL, Ramakrishnan V et al. Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology 2002; 60: 2817.
  • 120
    Macdonald OK, Schild SE, Vora SA et al. Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy. J. Urol. 2003; 170: 18337.
  • 121
    Katz MS, Zelefsky MJ, Venkatraman ES et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J. Clin. Oncol. 2003; 21: 4839.
  • 122
    Catton C, Gospodarowicz M, Warde P et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother. Oncol. 2001; 59: 5160.
  • 123
    Schild SE. Radiation therapy (RT) after prostatectomy: the case for salvage therapy as opposed to adjuvant therapy. Int. J. Cancer 2001; 96: 948.
  • 124
    Zietman AL, Chung CS, Coen JJ et al. 10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study. J. Urol. 2004; 171: 21014.
  • 125
    Pilepich MV, Krall JM, John MJ et al. Hormonal cytoreduction in locally advanced carcinoma of the prostate treated with definitive radiotherapy: preliminary results of RTOG 83–07. Int. J. Radiat. Oncol. Biol. Phys. 1989; 16: 81377.
  • 126
    Pilepich MV, Caplan R, Byhardt RW et al. Phase trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy: report of RTOG 85–31. J. Clin. Oncol. 1997; 15: 1013121.
  • 127
    Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma–long term results of phase RTOG study 85–31. Int. J. Radiat. Oncol. Biol. Phys. 2005; 61: 1285190.
  • 128
    Lawton CA, Winter K, Murray K et al. Updated results of the phase RTOG trial 85–31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int. J. Radial Oncol. Biol. Phys. 2001; 49: 937146.
  • 129
    Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med. 1997; 337: 295300.
  • 130
    Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study). Lancet 2002; 360: 1036.
  • 131
    Pilepich MV, Krall JM, Al-Sarraf M et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45: 61623.
  • 132
    Pilepich MV, Winter K, John MJ et al. Phase radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 2001; 50: 124352.
  • 133
    Hanks GE, Pajak TF, Porter A et al. Phase trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92–02. J. Clin. Oncol. 2003; 21: 397228.
  • 134
    Roach M 3rd, DeSilvio M, Lawton C et al. Phase trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J. Clin. Oncol. 2003; 21: 190411.
  • 135
    D'Amico AV, Manola J, Loffredo M et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 8217.
  • 136
    D'Amico A, Whittington R, Malkowicz S et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 96974.
  • 137
    Roach M, Lu J, Pilepich MV et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on radiation therapy oncology group clinical trials. Int. J. Radiat. Oncol. Biol. Phys. 2000; 47: 60915.
  • 138
    Kattan M, Zelefsky M, Kupelian P et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J. Clin. Oncol. 2000; 18: 33529.
  • 139
    Pollack A, Zagars GK, Starkschall G et al. Prostate cancer radiation dose–response: results of the M.D. Anderson Phase randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 2002; 53: 1097105.
  • 140
    Deger S, Boehmer D, Turk I et al. High dose rate brachytherapy of localized prostate cancer. Eur. Urol. 2002; 41: 4206.
  • 141
    Wallner K, Merrick G, True L et al. 125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcome from a prospective randomized multicenter trial. Int. J. Radiat. Oncol. Biol. Phys. 2003; 57: 1297303.
  • 142
    American Society for Therapeutic Radiology and Oncology Consensus Panel Consensus statement. Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int. J. Radiat. Oncol. Biol. Phys. 1997; 37: 1035341.
  • 143
    Vicini FA, Kestin LL, Martinez AA. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 1999; 45: 55361.
  • 144
    Taylor JM, Griffith KA, Sandler HM. Definitions of biochemical failure in prostate cancer following radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2001; 50: 121219.
  • 145
    Pollack A, Zagars GK, Antolak JA et al. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int. J. Radiat. Oncol. Biol. Phys. 2002; 54: 67785.
  • 146
    Tsushima T, Nasu Y, Saika T et al. Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist. Urol. Int. 2001; 66: 1359.
  • 147
    Boccardo F, Rubagotti A, Battaglia M et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J. Clin. Oncol. 2005; 23: 808015.
  • 148
    Wirth M, Tyrrell C, Wallace M, et al. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 2001; 58: 1464151.
  • 149
    See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T. Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. Eur. Urol. 2003; 44: 5127;discussion 517–18.
  • 150
    Iversen P, Johansson JE, Lodding P, et al. Scandinavian Prostatic Cancer Group. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3 year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J. Urol. 2004; 172: 187186.
  • 151
    Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostate cancer: initial results of the Medical Research Council Trial. Br. J. Urol. 1997; 79: 2353246.
  • 152
    Labrie F, Dupont A, Belanger A, et al. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J. Steroid Biochem. 1985; 23: 8333841.
  • 153
    Prostate Cancer Trialists ‘Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995; 346: 2656269.
  • 154
    Prostate Cancer Trialists ‘Collaborative Group. Maximal androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355: 149141498.
  • 155
    Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med. 1998; 339: 103642.
  • 156
    Schmitt B, Wilt TJ, Schellhammer PF, et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 2001; 57: 7272732.
  • 157
    Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002; 95: 3616376.
  • 158
    Klotz L. Combined androgen blockade in prostate cancer: meta-analyses and associated issues. BJU Int. 2001; 87: 806013.
  • 159
    Tannock IF, de Wit R, Berry WR et al. 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004; 351: 150212.
  • 160
    Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004; 351: 151320.
  • 161
    Holmberg L, Bill-Axelson A, Helgesen F et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N. Engl. J. Med. 2002; 347: 7819.
  • 162
    Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N. Engl. J. Med. 2005; 352: 197784.
  • 163
    Chodak GW, Thisted RA, Gerber GS et al. Results of conservative management of clinically localized prostate cancer. N. Engl. J. Med. 1994; 330: 2428.
  • 164
    Carter CA, Donahue T, Sun L et al. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J. Clin. Oncol. 2003; 21: 40018.
  • 165
    Choo R, Klotz L, Danjoux C et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J. Urol. 2002; 167: 16649.
  • 166
    Cooperberg MR, Broering JM, Litwin MS et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE, a national disease registry. J. Urol. 2004; 171: 1393401.
  • 167
    Bacon CG, Giovannucci E, Testa M et al. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J. Urol. 2001; 166: 180410.
  • 168
    George N. Therapeutic dilemmas in prostate cancer: justification for watchful waiting. Eur Urol. 1998; 34 (Suppl 3): 336.
  • 169
    Kakehi Y. Watchful waiting as a treatment option for localized prostate cancer in the PSA era. Jpn. J. Clin. Oncol. 2003; 33: 15.
  • 170
    Smith JA Jr, Soloway MS, Young MJ. Complications of advanced prostate cancer. Urology 1999; 54 (6A Suppl):814.
  • 171
    Scher HI, Chung LW. Bone metastases: improving the therapeutic index. Semin. Oncol. 1994; 21: 630356.
  • 172
    Japanese Society for Palliative Medicine, creation Committee of the clinical guideline for pain control in cancer patient. Evidence-Based Guideline for Pain Control in Cancer Patient. Shinko Trading Co., LTD., Tokyo, 2000.
  • 173
    Arcangeli G, Giovinazzo G, Saracino B et al. Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration. Int. J. Radiat. Oncol. Biol. Phys. 1998; 42: 111926.
  • 174
    Bolger JJ, Dearnaley DP, Kirk D et al. Strontium−89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron Investigators Group. Semin. Oncol. 1993; 20 (3 Suppl 2): 3223.
  • 175
    Quilty PM, Kirk D, Bolger JJ et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother. Oncol. 1994; 31: 3340.
  • 176
    Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl. Cancer Inst. 2002; 94: 145868.
  • 177
    Ross JR, Saunders Y, Edmonds PM et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003; 327 (7413): 469.
  • 178
    Sorensen S, Helweg-Larsen S, Mouridsen H et al. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur. J. Cancer 1994; 30A: 227.
  • 179
    Young RF, Post EM, King GA. Treatment of spinal epidural metastases. Randomized prospective comparison of laminectomy and radiotherapy. J. Neurosurg. 1980; 53: 7418.
  • 180
    Crain DS, Amling CL, Kane CJ. Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. J. Urol. 2004; 171: 66871.
  • 181
    Kraus PA, Lytton B, Weiss RM, Prosnitz LR. Radiation therapy for local palliative treatment of prostatic cancer. J. Urol. 1972; 108: 61214.
  • 182
    Oefelein MG. Prognostic significance of obstructive uropathy in advanced prostate cancer. Urology 2004; 63: 111721.
  • 183
    Watkinson AF, A’Hern RP, Jones A et al. The role of percutaneous nephrostomy in malignant urinary tract obstruction. Clin. Radiol. 1993; 47: 3225.
  • 184
    Docimo SG, Dewolf WC. High failure rate of indwelling ureteral stents in patients with extrinsic obstruction: experience at 2 institutions. J. Urol. 1989; 142: 2779.
  • 185
    Hasegawa T. Appraisal of Guidelines for Research and Evaluation Agree Instrument. [Cited 15 October 2004.]Available from URL: http://www.mnc.toho-u.ac.jp/mmc/guideline/AGREE-final.pdf